APA (7th ed.) Citation

Moek, K. L., Fiedler, W. M., Einem, J. C. v., Verheul, H. M., Seufferlein, T., Groot, D. J. d., . . . Ettrich, T. J. (2018). 427PPhase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma. Annals of Oncology, 29, N.PAG. https://doi.org/10.1093/annonc/mdy279.414

Chicago Style (17th ed.) Citation

Moek, K L., et al. "427PPhase I Study of AMG 211/MEDI-565 Administered as Continuous Intravenous Infusion (cIV) for Relapsed/refractory Gastrointestinal (GI) Adenocarcinoma." Annals of Oncology 29 (2018): N.PAG. https://doi.org/10.1093/annonc/mdy279.414.

MLA (9th ed.) Citation

Moek, K L., et al. "427PPhase I Study of AMG 211/MEDI-565 Administered as Continuous Intravenous Infusion (cIV) for Relapsed/refractory Gastrointestinal (GI) Adenocarcinoma." Annals of Oncology, vol. 29, 2018, p. N.PAG, https://doi.org/10.1093/annonc/mdy279.414.